PD-1、LAG-3在弥漫大B细胞淋巴瘤患者外周血CD8^(+)T细胞上的表达及临床意义  

Expression and clinical significance of PD-1 and LAG-3 on peripheral blood CD8^(+)T cells in patients with diffuse large B-cell lymphoma

作　　者：刘颖[1] 詹凌波 王蕾[1] 王新有[1] 范文霞 孙明玲[1] 赵冠云 郭新红[1] LIU Yingi;ZHAN Lingbo;WANG Lei;WANG Xinyou;FAN Wenxia;SUN Mingling;ZHAO Guanyun;GUO Xinhong(Hematologic Disease Center,the First Affiliated Hospital of Xinjiang Medical University,Xinjiang Uygur Autonomous Region Institute of Hematology,Urumqi 830054,China;School of Clinical Medicine,Zhejiang University,Hangzhou Zhejiang 310012,China)

机构地区：[1]新疆医科大学第一附属医院血液病中心新疆维吾尔自治区血液病研究所,乌鲁木齐830054 [2]浙江大学医学院临床医学院,杭州310012

出　　处：《新疆医科大学学报》2022年第9期998-1003,共6页Journal of Xinjiang Medical University

基　　金：新疆维吾尔自治区自然科学基金(2019D01C284)。

摘　　要：目的探讨程序性死亡受体-1(programmed cell death-1,PD-1)、淋巴细胞活化基因-3(lymphocyte activation gene-3,LAG-3)在弥漫大B细胞淋巴瘤(Diffuse Large B-cell Lymphoma,DLBCL)患者外周血CD8^(+)T细胞上的表达及临床意义。方法纳入17例初治DLBCL患者作为病例组,10例健康体检者作为对照组,采用流式细胞术检测病例组治疗前后及对照组外周血CD8^(+)T细胞上LAG-3、PD-1的表达,同时收集初治DLBCL患者的临床指标,分析DLBCL患者CD8^(+)T细胞上PD-1、LAG-3的表达与临床指标之间的关系。结果病例组PD-1^(+)LAG-3^(-)、PD-1^(-)LAG-3^(+)及PD-1^(+)LAG-3^(+)CD8^(+)T细胞比例均较对照组高(P<0.05),治疗后与治疗前相比,上述指标均下降(P<0.05);PD-1^(+)CD8^(+)T细胞比例与DLBCL患者B症状具有显著相关性(r=0.598,P<0.05)。结论DLBCL患者CD8^(+)T细胞上PD-1、LAG-3的比例较高,经治疗后表达降低;DLBCL患者CD8^(+)T细胞上PD-1的表达水平与患者的B症状具有一定相关性,提示PD-1、LAG-3参与了DLBCL疾病的发展。Objective To investigate the expression and clinical significance of programmed cell death-1(PD-1^(+))and lymphocyte activation gene-3(LAG-3^(-))on peripheral blood CD8^(+)T cells in patients with diffuse large B-cell lymphoma(DLBCL).Methods 17 patients with newly diagnosed DLBCL and 10 healthy subjects were included.The expression of LAG-3^(-)and PD-1^(+)on peripheral blood CD8^(+)T cells were detected by flow cytometry before and after the treatment and in healthy controls.The clinical parameters of newly diagnosed DLBCL patients were also collected to analyze the relationship between the expression of PD-1^(+)and LAG-3^(-)on CD8^(+)T cells and clinical parameters in DLBCL patients.Results The percentages of PD-1^(+)LAG-3^(-),PD-1^(+)LAG-3^(-)and PD-1^(+)LAG-3^(-)CD8^(+)T cells in DLBCL patients were higher than those in normal controls(P<0.05),and the above indicators were decreased after the treatment compared with those before the treatment(P<0.05);the percentages of PD-1^(+)CD8^(+)T cells were significantly correlated with B symptoms in DLBCL patients(r=0.598,P<0.05).Conclusion The expression levels of PD-1^(+)and LAG-3^(-)on CD8^(+)+T cells were higher in DLBCL patientsand were decreased after the treatment;the expression levels of PD-1^(+)on CD8^(+)T cells were correlated with B symptoms,suggesting that PD-1^(+)and LAG-3^(-)were involved in the development of DLBCL disease.

关 键 词：免疫抑制分子 程序性死亡受体-1 淋巴细胞活化基因-3 弥漫大B细胞淋巴瘤 

分 类 号：R551.2[医药卫生—血液循环系统疾病]